

NIH OFFICE OF EXTRAMURAL RESEARCH



FDAAA: NIH Extramural Grants Perspective

Gwynne L. Jenkins, PhD, MPHSpecial Assistant to the Director
Office of Extramural Programs, OER

ClinicalTrials.gov Results Database Train-the-Trainer Workshop, October 16, 2012





Objectives for This Section

- 1. Help you understand compliance:
 - Responsible Party (RP) role for applicable clinical trials (ACTs) supported by NIH grants
 - NIH certification of compliance with FDAAA
- 2. Help you avoid trouble spots:
 - Resources to help you
 - Tips

Note: NIH extramural grants only; not NIH contracts.





The NIH encourages registration and results reporting for <u>all NIH-supported clinical trials</u>, regardless of whether or not they are subject to FDAAA.



http://grants.nih.gov/ClinicalTrials_fdaaa/



Responsible Party & NIH Grants

- Sponsor [only one per trial] is:
 - IND/IDE* holder; if none, then:
 - The Grantee Institution is generally considered to be the Sponsor
 - Grantee is the "initiator" of the trial, having submitted the funding proposal
 - $\underbrace{\text{http://prsinfo.clinicaltrials.gov/ElaborationsOnDefinitions.}}_{\text{pdf}}$
 - Note:
 - Includes cooperative agreements & Center grants



* Investigational New Drug/Investigations Device Exemption



Criteria for PI as Responsible Party

- Sponsor may designate the <u>PI of the clinical</u> trial as RP provided that she or he:
 - 1. Is responsible for conducting the trial;
 - 2. Has access to and control over the data from the clinical trial;
 - 3. Has the right to publish the results of the trial; and
 - 4. Has the ability to meet all of the requirements for submitting information under the law.
- PI must meet <u>all</u> criteria to be designated





Designating the PI as RP (or Not)

- Sponsor is <u>not required</u> to designate the PI as the RP
- Carefully consider the implications of designating a PI as RP
 - What is in the best interest of the Sponsor?
 - After the trial ends?
 - After the PI leaves?





Understanding Requirement to Certify Compliance

- All ACTs supported in whole <u>or in part</u> by an NIH grant must be in full compliance with FDAAA
 - The RP has made all required submissions to ClinicalTrials.gov
- NIH certification of compliance with FDAAA applies to:
 - <u>All</u> grants supporting ACTs (even if only supporting one aspect of trial)
 - Grants where <u>neither</u> grantee nor PI is the RP of the ACT





Certifying of Compliance to NIH

Competing awards:

- SF 424: Part II, section 4.1.6
- PHS 398: Part II, section 4.1.6

Non-competing continuation progress report:

• PHS 2590: Section 2.2.6.D and section 4.6

Unrelated to the FDA certification of compliance





Current NIH Certification of Compliance

"Human Subjects" section under heading entitled "ClinicalTrials.gov":

- Registered trials provide:
 - NCT number/s
 - Brief Title/s
 - ID and contact info for the RP
- Trials <u>not yet registered</u> (<21 days since enrollment of the first participant):
 - Include a clear statement that the project includes an ACT which will require registration in ClinicalTrials.gov.





Upcoming NIH Certification of Compliance

- Research Performance Progress Reports (RPPR)
 - Simplified NIH certification of compliance with FDAAA in Type 5s (non-competing progress reports)
 - In pilot; begin roll-out in 2013
 - Enter NIH Grant number (not application number) in NCT record!
- To learn more:



http://grants.nih.gov/grants/rppr/index.htm



Record Retention for Clinical Trial Data

- Carefully consider requirements
- NIH Grantee Institution's responsibility
 - Minimum of 3 years after date of submission of final expenditures report to NIH
 - May be additional durations specified under CFR as well
- Requirements apart from those associated with NIH grants
 - State, other Agencies, etc.



11



What if NIH has concerns about compliance?

- Extramural Program Official may generate a notification email:
 - PD/PI, Business Official
 - Responsible party
 - NIH Grants Management
- FDAAA Issues Report from PRS (Protocol Registration System; NLM)
- Work quickly to respond and remedy
 - Bring trial and grant into compliance





Resources and Tips





NIH OER Resources to Help

"What NIH Grantees Need to Know about FDAAA"

http://grants.nih.gov/ClinicalTrials_fdaaa/

- Step-by-step guidance
- Flowcharts for ascertaining ACTs and RP
- "At-a-glance" requirements
- FAQs for NIH Grantees





Tips: Take a Team Approach

- Be aware of your Institution's approach/SOP
- Work as a team to identify ACTs and RPs
 - Sponsored research office, PI, Counsel
 - Work across institutions
 - Take actions <u>early</u> to clarify roles and responsibilities
- NIH's role
 - Resources
 - Cannot make determinations or register/report results on behalf of Grantee or RP



http://grants.nih.gov/grants/guide/notice-files/NOT-OD-09-147.html

1



Tip: Manage Risk Wisely

- Grantee Institutions as Sponsors
 - SOP? Outreach to stakeholders?
 - Monitor compliance?
 - All ACTs belong in Institutional account
 - Use personnel appropriately to fulfill FDAAA
 - Not necessary to have a someone designated as RP in order for him/her to enter data
 - Multi-user access, including user from outside of Institution
 - Implement appropriate record retention





Tips: Understand FDAAA

- Only the RP can register and report results
 - If trial is non-compliant, non-RP may not usurp RP's role
- Be attentive to rulemaking



17



The NIH encourages registration and results reporting for all NIH-supported clinical trials, regardless of whether or not they are subject to FDAAA.



http://grants.nih.gov/ClinicalTrials_fdaaa/